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010 The SSG Register – Tool for Clinical Research
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Objective: Present how the SSG register of bone and soft tissue
sarcoma patients has an important role for ensuring quality control
and as a basis for research projects.
Methods: The SSG Register was initiated in 1986 and more than
5000  patients  from  sarcoma  centers  in  Finland,  Norway  and
Sweden have been accrued. Patient data was registered at the par-
ticipating  institutions.  For  in-depth  studies,  clinical  data  was
reviewed and completed and the histopathology reclassified by the
SSG Pathology Board.
Results: For quality control, changes in referral and treatment of
soft  tissue  sarcoma  was  assessed  in  1851  soft  tissue  sarcoma
patients treated 1986–97. 63% were referred before open biopsy or
excision. Referral improved for deep-seated lesions but not subcu-
taneous. Fine-needle aspiration for cytologic diagnosis was used in
81%. The amputation rate decreased from 15% to 9%, surgical
margins  did  not  improve,  but  the  overall  use  of  radiotherapy
increased from 20% to 30%. Studies of local recurrence of soft
tissue sarcoma was based on 1613 patients treated 1986–95. The
local  recurrence  rate  was  17%,  but  for  high-grade  deep-seated
lesions 26%. After a first local recurrence, the risk of subsequent
recurrences was 30%, and the overall risk of amputation for local
recurrence was 22%. Local recurrence was associated with a high
risk of subsequent metastases but did not appear to be an impor-
tant cause of metastases. Studies on synovial sarcoma was based on
104 patients 1986–94. In a population based study of all patients
in Sweden during this time-period, the median age was 38 years,
and adjusted for age, the highest incidence was in 50–60 year olds.
The 5 and 7 years survival rates were 0.76 and 0.69. Large size,
local  recurrence,  Grade  IV,  MIB1  index  >  10,  and  SYT-SSX
fusion transcript was associated with metastases.
Conclusion: These studies show that a multi-institutional sarcoma
registry can be used both for monitoring treatment and as a basis
for in-depth studies. Based on these studies, guidelines for radio-
therapy in soft tissue sarcoma have been changed and we have been
able to show that referral to sarcoma centers have improved, lead-
ing to lower local recurrence rates.
014 RTOG 95-14: A Phase II Study of Neoadjuvant 
Chemotherapy (CT) and Radiation therapy (RT) in the 
Management of High Risk, High Grade, Soft Tissue 
Sarcomas (STS) of the Extremities and Body Wall: A 
Preliminary Report
W G Kraybill1, I J Spiro1, J Harris1, D S Ettinger1, A Trotti1, 
D R Lucas1, R Blum2, B R Eisenberg1
1Radiation Therapy Oncology Group, 2Eastern Cooperative Oncology 
Group
Objective: Introduction  and  Objectives:  Previous  reports  have
demonstrated improved disease- free survival in patients with large
high risk STS given neoadjuvant chemotherapy, radiation therapy
and post resection chemotherapy when compared with matched
controls not given chemotherapy. To evaluate this in the multi-
institutional  setting,  the  Radiation  Therapy  Oncology  Group
(RTOG) instituted a Intergroup Phase II trial of multi-agent CT
and preoperative  RT  combined  with  resection  in  patients  with
high-grade, high-risk STS of the extremities and body wall. Other
objectives were to develop a sarcoma working group for future
Phase II and Phase III clinical trials and to develop a tissue repos-
itory for future studies.
Methods: Methods: To assess toxicity, response rates, local con-
trol, distant  recurrence, survival and complications,  66  patients
with primary high grade (II or III of III) STS > 8 cm in maximum
diameter were treated with high-dose neoadjuvant CT (Modified
MAID) plus G-CSF and preoperative RT and 3 cycles of postop-
erative CT plus G-CSF. RT 44Gy was given in split courses of
22GY between cycles of CT.
Results: Results:  The  first  45  patients  had  potentially  1-year
follow-up and were eligible for analysis. Of which, forty-two MO
patients were analyzed. Median tumor diameter was 13 cm (Range
8–55). Thirty-four (81%) were Grade 3 tumors and 8 (19%) were
Grade 2 on a 3 grade system. Median follow-up was 2.35 years
(0.23–3.53). Thirty-five patients had clear surgical margins. Seven
patients had persistent disease with 4 having involved margins at
the time of resection, 1 patient having unresectable tumor due to
progression, and 2 patients requiring amputation secondary to dis-
ease. Two patients have relapsed locally, 3 patients have relapsed
in the lungs, 1 patient developed metastases in the right shoulder
and 2 patients developed a second primary. Six patients have died,
3 due to recurrent sarcoma, 2 due to a second primary, and 1 for
reasons pending clarification. The observed toxicities  were 76%
(32) Grade 4 hematologic toxicity and 24% (10) Grade 4 non-
Hematologic  toxicity.  Twenty-nine patients  (69%)  experienced
Grade 4 neutropenia and 12 (29%) Grade 4 thrombocytopenia.
Grade 4 skin toxicity in 5 patients (12%) was the most common
non-hematologic toxicity. While these expected toxicities are sig-
nificant,  85%  of  patients  completed  preoperative  CT,  93%  of
patients completed preoperative RT and 75% completed postop-
erative  chemotherapy.  Delayed  wound healing  was  reported  in
only 10 patients (26%). Estimated 2-year survival in these high-
risk tumors was 95%. There were 42 patients in the survival anal-
ysis and only 40 patients in other analysis. There is only survival
data on 2 patients. Of the 21 patients excluded from the analysis
because they were entered after April 1999, 16 (76%) have experi-
enced grade IV toxicity. Three of 21 (14%) have died, all of causes
related to the cancer under study.
Conclusions: While this is a preliminary report, the estimated 2-
year survival in these very high-risk patients is encouraging with
tolerable toxicity.
025 Successful Treatment of High Grade Soft Tissue 
Sarcoma with Induction (Neoadjuvant) Chemotherapy: 
Clinicopathological Analysis of Thick Capsule Formation 
Allowing Less Extensive Surgical Resection
Felasfa Wodajo, James C Wittig, Dhruv Kumar, Dennis Priebat, 
Robert M Henshaw, Martin M Malawer
Washington Cancer Institute Washington Hospital Center
Objective: The histologic changes occurring in the periphery, or
pseudocapsule, of sarcomas after  induction chemotherapy have
not previously been characterized in detail. We have used neoad-
juvant chemotherapy in lieu of preoperative radiation therapy for
limb sparing resections of large, high grade soft tissue sarcomas.
Microscopic examination of soft tissue tumors that have responded
well to induction chemotherapy demonstrates a thick, well defined
“capsule” surrounding necrotic tumor.
Methods: During the period of 1988 to the present, over 60 resec-
tions  for high-grade soft  tissue  sarcoma were performed by the
same surgeon. Nearly half were eligible for enrollment in an induc-
tion chemotherapy protocol consisting of intravenous adriamycin,S32 CTOS  abstracts
ifosfamide  and  intra-arterial  cis-platinum.  Resection  specimens
from  ten  patients  were selected  for histological  analysis. Six  of
these were high grade tumors with median tumor necrosis of 94%.
Two were high grade, poor responders (avg. 40% necrosis) and
two were high grade not having undergone neoadjuvant treatment.
Tumor  types  included  MFH  (3),  liposarcoma  (2),  leiomyosar-
coma (2), MPNST (1) and fibrosarcoma (1).
Results: In  5/6  patients  with  good  therapeutic  response,  the
tumor pseudocapsule was converted into an outer zone of densely
collagenized  fibrous  tissue  resembling  a  true  “capsule”  and an
inner zone of loose vascularized fibrous tissue. The outer zone did
not  contain  viable  tumor  cells.  Untreated  patients  and  poor
responders  demonstrated  thin,  interrupted  and  poorly  defined
outer zones and similarly vascular inner zones.
Conclusion: Limb sparing resection for soft tissue sarcoma in the
extremities often results in close surgical margins near critical neu-
rovascular structures. Preoperative chemotherapy resulting in for-
mation  of  a  thick,  collagenized  capsule  facilitates  resection  by
forming  a  safe  biological  border  for  dissection.  This  treatment
strategy may be considered analogous to induction chemotherapy
in osteosarcoma, which has permitted an increased rate of limb sal-
vage without increasing the rate of local recurrence.
041 A Retrospective Review of Mayo Clinic’s Phase II 
Clinical Trials of Advanced Sarcomas to Examine Survival 
Differences between Leiomyosarcomas of the GI Origin 
(GIST) Versus Non-GI Origin
S H Okuno, M R Mahoney, A M Olivera
Mayo Clinic
Objective: Recent  reports  suggest  that  patients  with  metastatic
GIST have inferior survival compared to patients with non-GI lei-
omyosarcoma. Previously GISTs were classified as leiomyosarco-
mas of the GI tract and clinical experience has shown that these
tumors of the gut behaved differently to treatment regimens than
similar tumors of non-GI origin. GISTs are now classified as mes-
enchymal tumors of Cajal cells which express c-kit and are respon-
sive to the small molecule STI-571. We wanted to verify if survival
differences were evident in our leiomyosarcoma patients (GIST vs.
non-GIST).
Methods: We reviewed from our previous 12 phase II studies for
advanced sarcoma  and identified  93  of  430  patients  diagnosed
with leiomyosarcoma. These patients were entered into the phase
II studies from 1971-1992 and largely when surgical options were
exhausted.  Treatments  included  adriamycin;  methyl-CCNU,
actinomycin D, cytoxan, vincristine;  adriamycin, imidazole  car-
boxamide, vincristine; pyrazofurin; cytoxan, adriamycin, cisplatin;
maytansine;  mitomycin,  adriamycin, cisplatin;  menogaril; inter-
feron gamma; ifosfamide, etoposide; ifosfamide, mitomycin, adri-
amycin, cisplatin; and taxotere. Because of limited samples and age
of the tissue, staining for c-kit (CD 117) was not performed.
Results: Thirty-six (39%) cases were classified as GIST (vs. 57
non-GIST). Ninety-one  patients  have  died.  Kaplan-Meier  esti-
mates are as follow:
Conclusion: In  our  retrospective  review  of  patients  on  12
advanced sarcoma Phase II clinical trials, we observed no statis-
tically  significant  difference  in  survival  between  patients  with
advanced leiomyosarcomas  of  the  GI  versus  those  of  non-GI
origin.
045 Sequential High-Dose Doxorubicin (DX) and
High-Dose Ifosfamide (IF) in Advanced Previously 
Untreated Soft Tissue Sarcomas (STS). A Multicenter 
Phase II Study of the Spanish Group for Research on 
Sarcomas (GEIS)
Joan Maurel, Antonio Lopez-Pousa, Jose Maria Buesa, Xavier 
Garcia del Muro, Carme Balaña, Antonio Casado, Javier 
Martinez-Trufero, Ramon De las Peñas, Javier Martin, Joaquin 
Bellmunt
Hospital Clinic Barcelona
Objective: DX and IF the most active drugs in adult STS have a
dose-response  effect  limited  by  its  hematological  toxicity  when
used in combination. We have designed a first-line sequential trial
of high-dose DX followed by high dose IF to maximize dose-inten-
sity and reduce toxicity.
Methods: Pts  with  advanced  STS  without  prior  exposure  to
chemotherapy were included. Prior radiotherapy was allowed if
given to non-indicator lesions. Gastrointestinal sarcomas (GIST)
and pts over 65 years were excluded. Treatment consisted of DX
90 mg/m2 q 14 days for 3 cycles followed by IF at 12.5 gr/m2 q 21
days for 3 cycles, both regimens with G-CSF support.
Results: From Dec’98 to May’01 we enrolled 56 STS pts, 53 were
eligible (8 locally unresectable, 45 metastatic). Median age was 52
years (range 24-65). performance status (PS) was 0 in 20 pts, 1 in
29 and 2 in 4. Metastatic sites: lung 31 pts (only lung 11 pts),
nodes 9, peritoneal 8, liver 7, bone 6. No. of sites: 1 in 32 pts, 2 or
more in 13. 43 patients are already evaluate for toxicity and 41 for
response (2 died without radiological assessment).  Median DX
dose was 43 mg/m2/w, 29 pts (68%) full dose, with grade III/IV
toxicity: neutropenia 9 pts (21%), neutropenic fever 3 pts (7%),
mucositis  12  pts (28%).There were 13  (32%) partial  responses
(PR). 8 pts did not receive HDI (3 progressive disease and poor
PS, 3  patients with severe no treatment-related  infection and 2
refused). Dose-intensity HDI was 3.1 gr/m2/w, with grade III/IV
neutropenia 15  pts  (42%),  neutropenic  fever  8  pts  (23%)  and
asthenia 10 pts (28%). After a full course of therapy 20 pts (48%)
achieved a PR. Two pts with a PR to DX progressed under HDI,
and 9 no responders to DX (8 SD and 1 PD) obtained a PR with
HDI. There were no toxic death.
Conclusion: This sequential dose-dense schedule is feasible, has
an acceptable toxicity profile and has a response rate similar  to
concomitant high dose IF-DX regimens.
049 Association between Breast Cancer and Cartilaginous 
Tumors: Phenotypic Characterization of a Hitherto 
Unrecognized Potential Hereditary Trait
M. Timmerman1, A. M. Cleton-Jansen1, M. J. v.d. Vijver1, C. van 
Asperen2, L. C. v.d. Broek1, P. C. Hogendoorn1
1Department of Pathology, Leiden University Medical Center, 
2Department of Medical Genetics, Leiden University Medical Center
Objective: Recently we documented a strong association between
the occurrence of cartilaginous tumors (enchondroma, chondrosa-
rcoma) and breast cancer in the same patient, using a nation-wide
case-control study. This study revealed an odds ratio of 7.62 for a
potential association of breast and cartilaginous tumors, pointing
statistically  strongly towards a genetic trait. This is furthermore
corroborated by the age of onset in patients with breast cancer as
the first tumor, which is about 10 years earlier than breast cancer
in the general population. Following this statistical/epidemiologi-
cal analysis we report on the phenotypic characterization of the
patient group.
Methods: The Dutch BRCA1 and BRCA2 family database was
searched  for  cases  recording  a  cartilaginous  tumor.  Moreover
using  the  national  pathology  database  the  tissue  blocks  of  all
patients reported to fulfil the associated tumors mentioned were
retrieved. Reported diagnoses were reviewed; breast cancer speci-
Rate GIST-Estimate
(95%)
Non-GIST-Estimate
(95%)
Median 1 yr (0.5-1.4 yrs) 1 yr (0.5-1.6 yrs)
1-year 53% (39-72%) 51%(39-66%)
2-year 11%(4-28%) 32%(22-46%)
Log-rank, p-value=0.45CTOS  abstracts S33
mens were classified and histologically characterized according to
the procedures used by the Breast Cancer Linkage Consortium. In
addition the cartilaginous tumors were analyzed with emphasis on
the central versus peripheral localization in the skeleton as previous
studies proved a different molecular mechanism to be operative in
the different subtypes.
Results: In the Dutch BRCA1 and BRCA2 database no case of
chondrosarcoma nor enchondroma was reported,  neither  within
the same patient nor within the pedigree pointing to a trait which is
different  from  the  aforementioned  breast  cancer  syndromes.
Remarkably all cartilaginous tumors are of one common histologi-
cal subtype being centrally localized whereas no peripheral cartilag-
inous tumor was registered. The breast tumors were histologically
heterogeneous with varying differentiation grade. Results on immu-
nohistochemical staining (p53, Bcl2, Her2-neu, p16, p21 estrogen
and progesterone receptor and E-cadherin) will be presented.
Conclusion: Evidence  is  presented  that  the  recently  described
association between the occurrence of breast cancer and cartilagi-
nous  tumors  is  different  from  other  known  breast  cancer  syn-
dromes with a restricted spectrum of cartilaginous tumors.
057 Temozolomide as a 6-Week Continuous Oral Schedule 
in Advanced Soft Tissue Sarcoma: A Phase II Trial of the 
Spanish Group for Research on Sarcomas (GEIS)
X Garcia del Muro, A Lopez Pousa, J M Buesa, J Martin, 
A Poveda, I Bover, P Escudero, J Martinez Trufero, A Casado
Institut Catala d’Oncologia
Objective: Temozolomide is an oral imidazotetrazine derivative,
that lacks activity against soft tissue sarcoma (STS) at standard
doses. Extended continuous oral administration mimics continu-
ous infusion, and increases drug exposure (Ca Res 1998;58:4363).
Methods: A multicenter phase II study was performed to assess
the activity and toxicity of Temozolomide administered at a dose
of 75 mg/m2/day, as a 6-week oral continuous schedule every 9
weeks, in adult patients (pts) with previously treated STS. From
November 1999 to date, 30 pts with advanced STS and non-irra-
diated measurable lesions were included into the study.
Results: At present, 27 pts were evaluable: 2 were inelegible and 1
refused treatment. Median age was 51 (29–76) years; 11 male and
16 female; PS: 0:9, 1:14, 2:4 pts. Histologic types were: GIST:4,
MFH:5, fibrosarcoma:3,  leiomyosarcoma:4,  liposarcoma:2,  angi-
osarcoma:2, mixed mullerian tumor:2, and others:5. Grade: III:15,
II:9, I:3 pts. Prior regimens included doxorubicin and Ifosfamide in
26 and 25 pts, respectively. A total of 42 cycles were administered.
Six pts did not receive a complete cycle of treatment due to: 3 rapid
progression, 2 early death from disease, 1 pulmonary thromboem-
bolism, and they were considered as treatment failures. There were
4 PR and 3 SD (Overall response rate: 15%, 95% CI: 4–34). Partial
responses were seen in 2 pts with uterine leiomyosarcoma, 1 mixed
mullerian tumor and 1 GIST, and they lasted 14, 10+, 7 and 4
months. Hematological toxicity was: Neutropenia G-IV:1, G-III:1,
G-II:2 pts, Thrombocytopenia GIII:2, GII:3 pts, Anemia G-III:4,
G-II:3  pts).  Non-hematological  toxicity  was:  Nausea  G-II:3  pts,
Vomiting G-II:4 pts, Asthenia G II:4 pts.
Conclusion: Temozolomide at this extended continuous schedule
has activity against STS, appears to be well tolerated, and deserves
further evaluation, specially against uterine sarcomas.
059 An Overview of Treatments Results in Osteosarcoma: Is 
there a need for a Global Collaboration?
Sigbjørn Smeland
Norwegian Radium Hospital
Objective: To overview the treatments results in high-grade oste-
osarcoma and to outline the need for international collaboration to
obtain further improvements.
Methods: Review the literature of treatment results in high-grade
osteosarcoma. Published results from prospective phase II studies
including  more  than  100  patients  and  randomized  studies  are
included in this analyses.
Results: High-grade osteosarcoma are rare tumors that make up
approx. 0.1 % of all malignant tumors. Introduction of intensive
chemotherapy has significantly improved the prognosis for patients
with  non-metastatic  disease  and  most  patients  with  extremity
localized tumors are currently operated with limb saving proce-
dures. However, there have been no major improvements in out-
come for the last 15 years and subgroups of patients still harbor a
very poor prognosis. Most progress in osteosarcoma treatment is
obtained from prospective phase II studies in patients with non-
metastatic extremity localized tumors in patients aged < 40 years
(classical osteosarcoma). The best centers report a 5-year overall
survival of 70% and currently more than 80% of the patients are
operated with a limb saving approach. Poor prognostic factors at
time  of  diagnosis  include  presence  of  metastatic  disease,  axial
localization and large tumor volume. Age is not a consistent prog-
nostic factor in osteosarcoma. Surgical margins, tumor necrosis
and treatment duration are important treatment related factors.
Due  to  difference  in  post-operative  therapy  the  true  impact  of
tumor necrosis is hard to assess; in large randomized trials with
similar post-operative therapy to good and poor responders the dif-
ferences in event-free survival are in the range from 25 to 40%.
Most centers agree that a three-drug combination with methotrex-
ate, doxorubicin and cisplatinum should be given up-front to all
patients and several groups also include ifosfamide to all or sub-
groups of patients in primary treatment. The schedule of therapy
is still being investigated and important issues yet to be answered
are the optimal use ifosfamide and cumulative dose of doxorubicin.
Such answers are likely only to be obtained in randomized trials.
The lack of progress in treatment of osteosarcoma for the last 15
years justify the introduction of novel treatment approaches and
specially to patients with an inherently poor prognosis. Candidate
agents include interferon-a and the immunostimulator, muramyl-
tripeptide. For relapsed patients the prognostic factors important
for outcome are in addition to surgical remission, extent of and
time to relapse and application of adequate second-line chemo-
therapy. The benefit of radiotherapy for patients with inoperable
disease/intralesional surgery is debated and needs further elucida-
tion. Even with maximal doses of chemotherapy, the prognosis for
patients with primary metastatic disease is dismal and there is no
support in current literature for the use of myeloablative chemo-
therapy. In the Scandinavian Sarcoma Groups database containing
485 patients with osteosarcoma, 30% of the patients belongs to a
heterogeneous  group  of  patients  with  non-extremity  localized
tumors and/or secondary osteosarcomas and/or age> 40 years, that
up to date have been excluded from most (inter)national trials.
The treatment principles  are based on data obtained from trial
conducted on mainly classical osteosarcomas assuming a similar
biology for the whole group of patients.
Conclusion: The rarity of osteosarcoma strongly argue for interna-
tional  collaboration  to  obtain  further  progress  in  treatment  and
insight in the biology of the disease. In primary treatment rand-
omized trails are needed both to optimize the scheduling of the cur-
rently known active drugs and to test out novel treatment agents.
For non-classical osteosarcomas and relapsed patients international
prospective phase II studies are needed to test out treatment regi-
mens and to identify prognostic factors in these patients.
067 Fertility in Young Adults Following Chemotherapy for 
High-Grade Bone Sarcomas
Richard D Lackman, Kathy Henderson, Rakesh Donthineni-Rao
Department of Orthopaedics University of Pennsylvania
Objective: Little has been reported in the literature regarding the
effects of chemotherapy on the fertility of young patients treated
for high-grade bone sarcomas.S34 CTOS  abstracts
Methods: We  retrospectively  reviewed  patients  with  osteosar-
coma  and Ewing’s  sarcoma  treated by  the  senior  author, from
1985-94. The chemotherapeutic agents included adriamycin, cis-
platin, methotrexate, ifosfamide, cytoxan, and vincristine. Patients
were queried  about  attempts  at  childbirth  and history  of preg-
nancy.
Results: Positive reports included 10 males and 5 females with a
mean age at diagnosis of 18 years (range 12 to 26). The mean time
to the first conception following cessation of chemotherapy was 5.5
years (range 1 to 11). All the couples except one, attempting con-
ception  were  successful  without  any  complications  during  the
pregnancy and without any congenital abnormalities of the babies.
The unsuccessful couple underwent a battery of testing and the
partner without a history of cancer was reported to be infertile.
None of the couples utilized fertility-enhancing drugs.
Conclusion: While some articles have suggested that the effects of
chemotherapy on adolescents and young adults with high-grade
sarcomas are transient, actual pregnancies have not been studied.
We found successful conception and subsequent birth of normal
children, and should be the expectation for these patients.
074 The Mutation Analysis of NFAT1 in Chondrosarcoma
Tomoki Aoyama1, Satoshi Nagayama3, Takeshi Okamoto1, 
Taisuke Hosaka1, Takeharu Nakamata1, Koichi Nishijo1, 
Tomitaka Nakayama2, Takashi Nakamura2, Junya Toguchida1
1Institiute for Frontier Medical Science Kyoto University, 2Department 
of Orthopaedics Kyoto University, 3Department of Surg. Surgical Basic 
Science Kyoto University
Objective: NFAT (nuclear factor of activated T cell) is a family of
transcription factor regulating gene expression in the immune sys-
tem. In NFAT1(-/-) mice, however, ectopic proliferation of carti-
lageous  tissues  were  observed,  some  of  which  resembled  with
chondrosarcomas (Ranger, et al. 2000). These results suggest that
in addition to the role in the immune system, NFAT1 is an impor-
tant  regulator  in  chondrocyte  proliferation/differentiation,  and
may have a role as a tumor suppressor gene in chondrosarcomas.
From this standpoint, we investigated the mutation analysis of the
NFAT1 gene in human chondrosarcomas.
Methods: From  the  cDNA  sequence  and  GeneBank  human
genome information, we were able to determine the genomic struc-
ture of NFAT1 gene, which consisted of 10 exons. Fifteen sets of
PCR primers were designed to amplify the entire coding sequences
including  intron  sequences  at  exon-intron  boundaries.  Initial
screening was performed by PCR-SSCP in 26 cases of chondrosa-
rcomas, and samples showing abnormal bands were further inves-
tigated by direct sequence. The expressions of NFAT1 in tumor
samples were analyzed by RT-PCR in 15 of 26 cases. The expres-
sions of NFAT1 was also analyzed in 10 cases of osteosarcoma, 23
cases of soft tissue sarcomas, and 4 cases of lipomas. Cultured cell
lines of osteosarcomas and mesenchymal stem cell (MSC) were
also analyzed.
Results: We found single base change in the coding sequences at
five  sites,  of  which  three,  C373G(Val51Val),
C1015G(Pro265Pro),  C1723A(Ile501Ile)  did  not  alter  the
coding  amino  acid.  In  other  two sites,  A1557T  (His446Leu),
C2859T(Pro880Leu),  identical  base  changes  were  present  in
patients normal somatic cells, denying the possibilities of somatic
mutations. Therefore, all of five base changes seemed to be single
nucleotide polymorphisms, and not disease-relating mutations.
The expression of NFAT1 was observed in all of examined chon-
drosarcomas (15/15). In addition, NFAT1 were also expressed in
9/10 osteosarcomas, 5/5 synovial sarcomas, 3/5 leiomyosarcomas,
2/3 myxoid liposarcomas, 1/3 well differentiated liposarcomas, 1/
3 MFH and 1/4 lipomas. We also found the expression of NFAT1
in most of osteosarcoma cell lines (6/7), indicating that messages
found in primary samples were not merely derived from infiltrat-
ing  lymphocytes.  The  expression  of  NFAT1  was  detected  in
undifferentiated MSC, and retained after the induction of chon-
drogenesis or osteogenesis, but disappeared after the induction of
adipogenesis.
Conclusion: The  results  in  this  study  suggest  that  the  NFAT1
gene  is  unlikely  to  be  a  tumor  suppressor  in  chondrosarcoma.
Because  the  expression  was  detected  in  various  mesenchymal
tumors and also MSC, the NFAT1 may play a role in proliferation
and/or differentiation of mesenchymal cells. Down-regulation of
the  expression  after  adipogenic  induction  in  MSC,  and  lower
expression in tumors derived from adipose tissues suggest that one
of the roles of NFAT1 in mesenchymal tissues is the inhibition of
adipogenesis.
075 Novel Type of EWS-Chop Fusion Gene in Two Cases of 
Liposarcomas with Aggressive Clinical Features and 
Atypical Histopathological Findings
Tomitaka Nakayama1, Taisuke Hosaka2, Yasuaki Nakashima3, 
Katsuyuki Kusuzaki4, Takeharu Nakamata2, Tomoki Aoyama2, 
Takeshi Okamoto2, Koichi Nishijo2, Takashi Nakamura1, Junya 
Toguchida2
1Department of Orthopaedic Surgery Kyoto University, 
2UniversityInstitiute for Frontier Medical Science Kyoto University, 
3Department of Pathology Kyoto University, 4Department of 
Orthopaedic Surgery Kyoto Prof.Univ.of Med.
Objective: Chimeric proteins  consisting  of TLS and CHOP or
EWS and CHOP are characteristic markers for myxoid liposarco-
mas (MLS). At least nine different structure of TLS-CHOP fusion
transcripts due to different breakpoints or alternative splicing were
reported, whereas only one type consisting of exon 1 to 7 of EWS
and exon 2 to 4 of CHOP gene was so far reported in the case of
EWS-CHOP fusion gene. Here we described our analyses of 21
MLS cases, and found a novel type of EWS-CHOP fusion gene in
two cases with unique clinical and histopathological findings.
Methods: RNAs  and  DNAs  were  extracted  from  surgically
resected tumor tissues of 21 MLSs. RNAs with appropriate quality
were  available  in  18  cases,  and cDNAs  were  synthesized  from
them. Using these cDNAs as a template, either TLS or EWS-spe-
cific  primer  was  used  in  combination  of  the  CHOP  primer  to
amplify TLS-CHOP or EWS-CHOP fusion genes, respectively.
Amplified  fragments  were  directly  sequenced  to  determine  the
structure of fusion genes. In the remaining three cases, genomic
long-distance PCR was performed to amplify genomic fragments
encompassing the genomic fusion points.
Results: By the combination of RT-PCR and genomic long-dis-
tance  PCR  analysis,  we  found  either  TLS-CHOP  or  EWS-
CHOP fusion genes in all of 21 cases. Among them, 17 cases
(81%) were found to have TLS-CHOP fusion genes. The struc-
ture of these fusion genes were type 1 in five cases, type 2 in eight,
type 3 in one, type 4 in two and type 5 in one case according to
the classification of previous reports including ours. EWS-CHOP
fusion genes were detected in four cases (19%), of which two
were found to consist of exon 1 to 7 of EWS and exon 2 to 4 of
CHOP, This structure is identical with those of five cases with
EWS-CHOP fusion genes in previous literatures. The structure
of the other two cases was found to be a novel one, consisting of
exon 1 to 10 of EWS and exon 2 to 4 of CHOP gene. The clinical
and pathological findings of these two cases with this novel EWS-
CHOP fusion gene were quite remarkable in contrast with other
cases. Both presented a rapid growing huge mass, showing good
response  to  preoperative  chemotherapy,  but  developing  local
recurrence within 12 months. Tumor tissues  showed monoto-
nous proliferation of small cells with minimum adipocytic fea-
tures  in abundant myxoid  matrix  and few  vascular structures.
These features were not compatible with classic myxoid or round
cell liposarcoma, and also clearly different from pleomorphic or
well-differentiated liposarcoma.CTOS  abstracts S35
Conclusion: The fact that clinical and histopathological findings
of two cases with a novel EWS-CHOP gene shared several unique
features suggest the  unique property of this  type of rare fusion
gene,  which  may be  related  to  develop  a  distinct  type  of lipo-
sarcomas.
081 Pulmonary Metastasis in STS
Matthias Peiper, Thomas Streichert, Antja Heinecke, Jacob 
R. Izbicki, Wolfram Trudo Knoefel
Dep. of General Surgery, University Hospital Hamburg-Eppendorf, 
Germany
Objective: The lungs compromise a predilection site for pulmo-
nary STS metastasis.
Methods: A retrospective analysis of all patients operated on pul-
monary metastasis of STS between 1988 and 1999 was performed.
Patients and tumor characteristics as well as surgical and patholog-
ical results where evaluated.
Results: 52 patients (31 female, 21 male) with a median age of 44
(18-75) years were operated. Primary tumors included leiomyosa-
rcomas (n=13, 23%), MFH (n=10, 19%), MPNST (n=6, 13%)
and 23  tumors  of 11  other entities  42%  of  patients  have been
already  treated  with  primary  STS  in  our  institution.  Primary
tumors were located subcutaneous in 12 patients, subfascial in 25
patients and in 15 patients in parenchymatous organs. Half of pri-
mary STS were poorly differentiated, while 30% were moderate
and 20%  were well  differentiated. 29%  of primary  tumors  had
been resected achieving wide margins (R0), 71% R1. In 12.5% of
patients, distant metastasis were present at initial diagnosis. In 40
patients chemotherapy had been administered (not in randomized
trials), 26 of these after diagnosis of pulmonary metastasis. In 28
patients local recurrence occurred, in 25 of these before or simul-
taneously with pulmonary metastasis. Patients were operated by
thoracotomy or sternotomy no patient was operated using thora-
coscopy. Up to 4 operations were performed per patient and up to
38 pulmonary tumors were resected. At the end of follow-up 14
patients are alive, while 38 died due to tumor disease. Mean over
all survival time was 37 months and 20 months after metastasec-
tomy. No significant  statistic  parameters  were found associated
with reduced survival.
Conclusion: Though most patients with pulmonary STS metasta-
sis will eventually die due to tumor disease, cures are noted and
over all survival is better than and most other malignancies. Even
recurrent metastasectomy may be indicated in selected patients.
083 The Immediate Re-Excision of Soft Tissue Sarcomas 
After Inadequate Initial Surgery
Thomas Streichert, Matthias Peiper, Antje Heinecke, Wolfram 
Trudo Knoefel, Jacob R. Izbicki
Dep. of General Surgery, University Hospital Hamburg-Eppendorf
Objective: Soft tissue sarcoma (STS), a rare tumor entity, is often
mistreated by local excision because of their supposed benignity.
This results in local recurrence-rates up to 70%. Since 1988 we
perform a re-excision in patients where initial resection was made
not  achieving  wide  margins.  Most  patients  were  referred  for
assumed  adjuvant  therapy,  but  interdisciplinary  evaluation  of
patients and charts revealed initial close resection margins.
Methods: From 1988 until 1998 287 patients were treated in our
department  suffering  from  primary  soft  tissue  sarcomas  of  the
extremities or of the trunk. 115 patients were treated before with
simple  excision not achieving adequate margins. These patients
were re-resected in-between the next 9 to 37 days after primary
resection.
Results: 67 male and 48 female patients with a mean age of 47
years were included into this study. The STS were located either
at the extremities (lower extremity: n=67, upper extremity: n=26)
or at the trunk (n=22). 62 of them were subcutaneous, 53 subfas-
cial. The histological grade was in n=45 cases G1, in n=40 G2 and
in n=30 G3. All of the subcutaneous and 33 subfascial STS were
treated locally by wide resection, 20 of the latter received a com-
partmental resection. In 102 patients a R0-resection was achieved,
13  resection  R1  patients  –  refused  further surgery,  resulting  in
amputation.  In  53  cases  (46%)  the  histology  revealed  residual
tumor: 14  of them  multifocally and in 50  specimen tumor was
detected macroscopically. Adjuvant therapy was administered in
33  patients  and chemotherapy in 12  patients.  Local recurrence
occurred in 15 patients (13%). After a mean follow-up of 69 (17–
121) months, 87 patients were alive without evidence of disease,
and 7 were alive with tumors. 8 patients died tumor-related, 6 died
of other reasons.
Conclusion: In case of inadequate initial surgery the primary re-
excision should have highest priority in the multimodality treat-
ment concept, since nearly 50% showed a residual tumor though
were reported for being excised  completely.  The resection  with
wide margins  plays the key role for soft tissue  sarcoma therapy
leading to a smaller rate of recurrence and assumingly less distant
metastasis.
093 Alveolar Soft Part Sarcoma in Adults: Analysis of 
Clinical Features and Treatment Outcome in 19 Cases
Helen C. Swannie, Omar Al-Muderis, J. Meirion Thomas, Clive 
L. Harmer, Cyril Fisher, Ian R. Judson
Sarcoma Unit, Royal Marsden Hospital
Objective: Alveolar soft part sarcoma (ASPS) is a rare tumour,
accounting for approximately 1% of malignant soft tissue tumours.
Most centres see very few cases and the literature pertaining to
adults is sparse. The purpose of this study was to review the expe-
rience of our institution in treating adults presenting with ASPS
and  to  assess  strategies  for  management  of  metastatic  disease,
including systemic therapy and surgery.
Methods: The case records of 19 consecutive patients presenting
with alveolar soft part sarcoma aged 15 years and over between
1984 and 2000 were reviewed retrospectively. Data were evaluated
with respect to patient characteristics, location of primary tumour,
frequency and site of metastases, recurrence, treatment outcome
and death. Survival was defined as the interval between diagnosis
and death or last follow-up visit. PFS was defined as the time from
diagnosis to relapse, death, disease  progression, or most  recent
follow up visit. The last follow-up visit in the group was November
16, 2000 and the median follow up duration of surviving patients
is 68.1 months (range, 21.8 – 222.6).
Results: The 12 male and 7 female patients had a median age of
28 years (range 15 -51). 68% (13/19) of patients presented with
extremity tumours. Local recurrence was rare (1 patient) but 74%
of the patients (14/19) had developed metastatic disease. 47% (9/
19) had pulmonary metastatic disease at presentation with 26% (5/
19) developing metastatic disease more than 3 years after diagno-
sis. At last follow-up, 69% (13/19) were alive, 32% (6/19) were dis-
ease free and 37% (7/19) were alive with metastatic disease. No
objective responses to chemotherapy were observed in the 47% (9/
19) of patients who received chemotherapy for metastatic disease
but  of  the  9  who  underwent  pulmonary  metastasectomy,  7
achieved complete clearance, with only 2 of these recurring in the
thorax after surgery. 4 patients of the 9 (44%) remain disease free
at last follow-up.
Conclusion: ASPS is a rare disease entity in adults, characterised
by a high metastatic rate but indolent disease course. There is cur-
rently no effective systemic treatment but resection of pulmonary
metastases  may be curative and should be pursued aggressively
even if repeated metastasectomies are required.S36 CTOS  abstracts
104 Non-Viral Gene Transfer into Human Osteosarcoma 
Cells Using the Non-Liposomal Lipid Effectene – a Primer 
for Malignant Bone Tumor Gene Therapy Strategies
Detlev Gottschalk1, B. Schmitz2
1Department of Orthopedics – Connective Tissue Research, University 
clinic and Medical School, RWTH Aachen, and Interdisciplinary 
Centre for Clinical Research on Biomaterials (IZKF "Biomat.), 
RWTH Aachen, 2Department of Clinical Chemistry and 
Pathobiochemistry, RWTH Aachen
Objective: To elucidate the transfection efficacy of the new non-
liposomal lipid Effectene on human osteosarcoma cells used for
cancer treatment protocols in-vitro and the possible role of this
new transfection agent for cancer gene therapy strategies.
Methods: For transfection, a 4.7 kB plasmid (pEGFP-C1, Clon-
tech) was applied containing a CMV promotor and the enhanced
green fluorescent protein (EGFP) gene sequence, a red shifted var-
iant of the wild type GFP. For transfection of human primary oste-
oblast like cells (hOB) and a osteogenic, osteosarcoma cell line
(HOS58), using a modified standard protocol by quiagen, two dif-
ferent plasmid concentrations (0.4 ug, 1.0 m g) were used. Controls
were treated with Effectene reagent without prior DNA applica-
tion. For microscopic analysis, cells were washed in HBSS and
fixed in 4% paraformaldehyde for 20 min at RT, washed again in
HBSS and analyzed by standard microscopy and confocal laser
scan microscopy. For measuring transfection efficacy by FACScan
analysis cells were washed in HBSS, trypsinized and subsequently
analyzed on FACScalibur. PI (0.1 mg/ml) was added to each tube
to exclude dead cells. The amount of EGFP-expression was deter-
mined in the life gate.
Results: A linearity of transfection efficacy could be observed with
increasing amounts of the used plasmid concentrations in hOB.
Transfection with 0.4 ug plasmid DNA results in mean of about
6.5% of EGFP expressing cells. The EGFP expression varied from
weak to very strong fluorescence intensities. The amount of PI-
positive  cells  was determined  as  about  20%.  A  higher  plasmid
DNA  concentration  (1.0  m g)  resulted  in  increased  amount  of
EGFP expressing viable cells (transfection rate about 13%), but
effected also in a negative way the total amount of EGFP express-
ing living cells (about 18%). The transfection rate of HOS58 was
about 11% and 13% respectively but higher plasmid concentration
had no cell-toxic effect as in the non-malignant transformed hOB
system (living cells  79%  and 82%  respectively). An increase of
plasmid concentration had no significant effect on the transfection
rate in HOS58 but significantly decreased the amount of viable
hOBs.  Therefore,  future  gene  therapy  strategies  for  malignant
bone tumors should be performed with caution, even using non-
viral vectors.
Conclusion: Effectene used as new non-viral transfection agent,
here  proved  to  be  successful  on  human  primary  osteoblasts
(hOB)and a human osteosarcoma cell line (HOS58) has a high
reproducibility and a low cytotoxicity compared to other systems.
Moreover,  Effectene  works  in  the  presence  of  serum  without
restriction allowing longer incubation time. In addition, lower con-
centrations of DNA are needed. These items are of advantage in
cancer treatment protocols. Gene therapy for malignant bone dis-
ease is a challenge for the new decade of cancer treatment and
could  support  neoadjuvant chemotherapy  and/or  could  help  to
decrease  intrinsic  tumor  cell  resistance  to  chemotherapeutic
agents.
115 ET-743, A New Active Drug in Adult Soft Tissue 
Sarcoma: A Soft-Tissue and Bone Sarcoma Group/EORTC 
Phase II Trial
Axel Le Cesne1, Jean Yves Blay1, Ian Judson1, Alan Van 
Oosterom1, Jaap Verweij1, John Radford1, Paul Lorigan1, 
Elisabeth Gray1, Jose Jimeno2, Ole Nielsen1
1STBSG – EORTC Data Center, 2Pharma Mar
Objective: The main objectives of this multicenter phase II study
were to assess the activity and toxicity of ET-743 (Pharma Mar/
Spain) administered at a dose of 1500 m g/m2 as 24-hour CI every
3 weeks in patients (pts) with advanced sarcoma.
Methods: Pts  with  GIST  (group  (gp)  B)  received  ET-743  as
front-line chemotherapy (CT) while pts with documented progres-
sive STS (gp A and C) as 2nd/3rd line CT. Evaluation of response
in gp C was performed with the new system based on RECIST cri-
teria.
Results: between  5/99  and  11/00,  471  cycles  of  ET-743  were
administered to 132 pts (47, 28 and 57 in gp A, B and C respec-
tively). Toxicity (T) : there was no alopecia and no severe digestive
T. A reversible gde 3-4 transient elevation of transaminases was
seen in about 40% of pts in all gps. Febrile neutropenia (N) and
gde 3-4 N were observed in 15, 7 and 3% and 45, 48 and 58% of
pts included in gps A, B and C respectively. Haematological T was
not cumulative (pts receiving from 1 to 14 cycles). There were 4
toxicity-related deaths in gp A. After protocol amendment (10/99)
requiring normal ALP at inclusion and ET-743  dose reduction
(1200 m g/m2) in case of an intercycle-rise in bil/ALP, the incidence
of  serious  T  has  been  significantly  decreased.  No  OR  were
observed in GIST pts. Among the 94 eligible pts in gp A and C,
there were 8 PR (OR rate of 9%), 48 NC (51%) (including 4 not
confirmed PR and 2  prolonged major MR) and 28 PD (30%).
Two patients are ongoing and 8 pts were not evaluable. The 6
months progression free survival (6PFS) for all included pts were
31,  24  and 28%  in gp A,  B  and C respectively.  Thirty six  pts
received at least 6 cycles of CT. The 6PFS observed in non-GIST
sarcoma  compares  favorably with  those  (6PFS:  18%)  obtained
with other active drugs tested in 2nd line CT in previous EORTC
trials (Van Glabbeke, ASCO 01). Median overall survival was 250
and 241 days for pts included in gp A and C respectively.
Conclusion: ET-743  is  an active  compound in  advanced STS.
Further studies with a shorter infusion time as single agent and/or
in combination are warranted.